ENIGMA
DEAD

Serial Number

90354435

Owner

CANADIAN NEUTRICEUTICAL HEALTH INC.

Attorney

Justin Brown

Filing Date

Dec 2, 2020

Add to watchlist:

No watchlists yet
View on USPTO

ENIGMA Trademark

Serial Number: 90354435

ENIGMA is a trademark filed by CANADIAN NEUTRICEUTICAL HEALTH INC. on December 2, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

CANADIAN NEUTRICEUTICAL HEALTH INC. (3 trademarks)

Bolton, Ontario L7E5C1 , CA

Entity Type: 03

Trademark Details

Filing Date

December 2, 2020

Registration Date

Not Registered

Published for Opposition

September 28, 2021

Goods & Services

Pharmaceutical preparations, namely, antivirals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Analgesic and muscle relaxant pharmaceutical preparations; Antimicrobial preservatives for pharmaceuticals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, injectable contraceptives; Potassium preparations for pharmaceutical purposes; Pharmaceuticals, namely, psychotropics; Pharmaceuticals, namely, lipid lowering agents; Pharmaceuticals, namely, inducers of erections; Pharmaceuticals, namely, antihelmintics; Pharmaceutical antitussive-cold preparations; Ocular pharmaceuticals; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, anticoagulants; Alcohol for pharmaceutical purposes; Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cardiovascular disorders; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Antibacterial pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti - infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Cardiovascular pharmaceuticals; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical products for treating respiratory diseases and asthma; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the treatment of inflammatory disorders; Pharmaceutical preparations for use in oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the treatment of viral infections; Pharmaceutical preparations for treating halitosis; Pharmaceutical preparations for treating hypoglycemia; Pharmaceutical preparations for the treatment of bone fractures; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating allergic rhinitis; Pharmaceutical preparations for treating asthma; Pharmaceutical products for the treatment of cancer

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 30, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 30, 2024 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 4, 2024 EXRA
SOU EXTENSION 5 GRANTED
May 3, 2024 EX5G
SOU EXTENSION 5 FILED
May 3, 2024 EXT5
SOU TEAS EXTENSION RECEIVED
May 3, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 25, 2023 EXRA
SOU EXTENSION 4 GRANTED
Nov 23, 2023 EX4G
SOU EXTENSION 4 FILED
Nov 23, 2023 EXT4
SOU TEAS EXTENSION RECEIVED
Nov 23, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 4, 2023 EXRA
SOU EXTENSION 3 GRANTED
May 2, 2023 EX3G
SOU EXTENSION 3 FILED
May 2, 2023 EXT3
SOU TEAS EXTENSION RECEIVED
May 2, 2023 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 12, 2022 EXRA
SOU EXTENSION 2 GRANTED
Nov 10, 2022 EX2G
SOU EXTENSION 2 FILED
Nov 10, 2022 EXT2
SOU TEAS EXTENSION RECEIVED
Nov 10, 2022 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 30, 2022 EXRA
SOU EXTENSION 1 GRANTED
Apr 28, 2022 EX1G
SOU EXTENSION 1 FILED
Apr 28, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 28, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 23, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 28, 2021 NPUB
PUBLISHED FOR OPPOSITION
Sep 28, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 8, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 25, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 25, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 25, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 25, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 25, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 12, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 11, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 11, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 28, 2021 GNRN
NON-FINAL ACTION E-MAILED
May 28, 2021 GNRT
NON-FINAL ACTION WRITTEN
May 28, 2021 CNRT
ASSIGNED TO EXAMINER
May 19, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 8, 2021 NWOS
NEW APPLICATION ENTERED
Dec 5, 2020 NWAP